LAS VEGAS /PRNewswire/ -- Noninvasive Medical Technologies Inc. (NMT), a medical device company pioneering highly advanced, award-winning medical assessment and communications solutions for military and civilian medical use, announced that the company has been awarded a sole source contract by the U.S. Air Force, valued at approximately $2.4 million, for continued development of the Multiple Casualty Assessment and Management System. Contracting activity is the Air Force Research Laboratory, Tyndall Air Force Base (contract number FA4819-09C-002).
Commenting on the award, Ronald McCaughan, Chairman and CEO of NMT, stated, "Our company was originally challenged by the U.S. Air Force to develop a casualty assessment and management solution back in early 2006. This most recent award represents the fourth contract we've received from the Department of Defense and the third as a Department of Defense prime contractor, with sole source provider designation. Moreover, it serves as a notable testament to NMT's engineering capabilities and to our team's proven ability to successfully meet and exceed crucial research and development milestones set for us by our Department of Defense partners."
The Multiple Casualty Assessment and Management System is a comprehensive, turnkey solution that incorporates NMT's patent-pending Etag, a noncontact hemodynamic monitoring device, with wireless communications, display technology, and advanced tactile sensors to simultaneously detect and monitor multiple casualties within 300 yards of a medic or first response team. Remotely activated, the system monitors each individual casualty from point of wounding to casualty evacuation and produces a necessary data record for follow-on casualty management. Further, the system provides a real-time communications link with a rear tactical command center, enhancing command's battlefield situational awareness and supplying meaningful ground intelligence for required logistical response and follow-on care.
NMT is also currently engaged in adapting its innovative Etag technology for commercial use. Branded as the NcIQ, market availability of this innovative device is currently pending review and clearance of a 510(k) submitted to the U.S. Federal and Drug Administration earlier this year. Once clearance is received from the FDA, NMT intends to pursue compelling market opportunities for the NcIQ that include applications in disaster response, underground coal mines, critical-care facilities, firefighting, EMT/ambulance service, and others.
According to Frost and Sullivan Research Analyst Zachary Bujnock, "While this system is pending FDA approval, it (NcIQ) has potential applications in many different kinds of emergency response. The use of complete noncontact monitoring is a perfect example of innovation, and in many ways is the future of patient monitoring, especially in remote settings."
NMT has also teamed with the National Aeronautics and Space Administration (NASA) on a joint research initiative involving parabolic investigations using the NcIQ device onboard Zero Gravity Corporation's modified Boeing 727 jet. More specifically, in association with NASA's FASTRACK project, the NcIQ is being used to perform continuous, noninvasive monitoring of human hemodynamics during changes in gravity. FASTRACK is a research platform created by NASA to enable its investigators to test experiments, apparatus, and analytical techniques in hardware compatible with the International Space Station.
Headquartered in Las Vegas, NV, Noninvasive Medical Technologies Inc. (NMT) has pioneered a suite of highly advanced, noninvasive medical assessment and communication tools and solutions that provide military and civilian medical care specialists with real-time situational awareness and critical life-saving intelligence. NMT's mission is to save lives by continually advancing the standard for noninvasive patient monitoring across the care continuum, while maximizing clinical, medical, and financial outcomes and promoting scientific innovation. For more information, please contact Laura Dolajak at 888-466-8552 or via email at [email protected].